Professor Davey Smith, Director of the UCSD Altman Clinical and Translational Research Institute, highlighted the significance of this collaboration, noting that there are currently no effective therapies for Long-COVID, which impacts millions worldwide.

Existing treatments for Long-COVID are limited as they typically target a single mechanism, which has hindered the development of effective therapies for this complex condition.

The clinical trial will be led by UCSD Professor Ajay Bharti, an infectious disease specialist with expertise in the neurocognitive effects of viral illnesses.

Hyundai Bioscience, founded in 2000 and listed on KOSDAQ, focuses on drug development through innovative delivery systems and repurposing existing drugs.

Xafty® was developed at Hyundai Bioscience's headquarters in South Korea, showcasing the company's commitment to addressing pressing health issues.

Xafty® is designed to alleviate Long-COVID symptoms by employing multiple therapeutic mechanisms, including inflammation inhibition and neuro-protection.

Long-COVID is characterized by a range of complex symptoms, including chronic fatigue, inflammation, and cognitive decline, which existing treatments fail to adequately address.

Dr. Bharti's background positions him as an ideal leader for this trial, which aims to explore innovative treatment options for Long-COVID.

Hyundai Bioscience USA has signed a Memorandum of Understanding with the University of California San Diego on September 18, 2024, to collaborate on addressing Long-COVID.

The partnership aims to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, an antiviral drug derived from niclosamide.